Barclays PLC Purchases 54,996 Shares of Artivion, Inc. (NYSE:AORT)

Barclays PLC raised its holdings in Artivion, Inc. (NYSE:AORT) by 346.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 70,877 shares of the company’s stock after acquiring an additional 54,996 shares during the quarter. Barclays PLC owned approximately 0.17% of Artivion worth $1,888,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Perceptive Advisors LLC lifted its position in shares of Artivion by 4.7% in the 2nd quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock worth $71,658,000 after purchasing an additional 124,725 shares during the period. Wellington Management Group LLP lifted its holdings in Artivion by 2.9% in the third quarter. Wellington Management Group LLP now owns 1,656,264 shares of the company’s stock valued at $44,090,000 after buying an additional 46,267 shares during the period. First Eagle Investment Management LLC boosted its position in Artivion by 4.9% during the second quarter. First Eagle Investment Management LLC now owns 598,148 shares of the company’s stock valued at $15,342,000 after acquiring an additional 27,906 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Artivion by 58.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock worth $9,074,000 after acquiring an additional 125,668 shares during the period. Finally, Bank of New York Mellon Corp raised its position in shares of Artivion by 0.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 301,992 shares of the company’s stock worth $7,746,000 after acquiring an additional 2,018 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Stifel Nicolaus raised their target price on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, September 13th. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 price objective on shares of Artivion in a research report on Tuesday, December 10th. Oppenheimer boosted their target price on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $34.00 price target on shares of Artivion in a report on Monday, December 9th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $31.80.

Artivion Price Performance

Shares of NYSE:AORT opened at $29.34 on Friday. Artivion, Inc. has a twelve month low of $16.48 and a twelve month high of $30.45. The stock’s 50 day moving average is $28.09 and its 200-day moving average is $26.49. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -1,467.00 and a beta of 1.75.

Insiders Place Their Bets

In other news, VP Andrew M. Green sold 7,618 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total value of $228,540.00. Following the completion of the sale, the vice president now directly owns 33,503 shares of the company’s stock, valued at $1,005,090. This represents a 18.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Amy Horton sold 4,329 shares of Artivion stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $29.66, for a total value of $128,398.14. Following the transaction, the chief accounting officer now directly owns 135,660 shares in the company, valued at approximately $4,023,675.60. The trade was a 3.09 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,447 shares of company stock worth $925,424. Insiders own 8.10% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.